130 related articles for article (PubMed ID: 37245245)
1. Discovery of berberine analogs as potent and highly selective p300/CBP HAT inhibitors.
Zhong X; Deng H; Long M; Yin H; Zhong Q; Zheng S; Gong T; He L; Wang G; Sun Q
Bioorg Chem; 2023 Sep; 138():106597. PubMed ID: 37245245
[TBL] [Abstract][Full Text] [Related]
2. Novel berberine derivatives as p300 histone acetyltransferase inhibitors in combination treatment for breast cancer.
Lai R; Lin Z; Yang C; Hai L; Yang Z; Guo L; Nie R; Wu Y
Eur J Med Chem; 2024 Feb; 266():116116. PubMed ID: 38215590
[TBL] [Abstract][Full Text] [Related]
3. Discovery, Structure-Activity Relationship, and Biological Activity of Histone-Competitive Inhibitors of Histone Acetyltransferases P300/CBP.
Wu F; Hua Y; Kaochar S; Nie S; Lin YL; Yao Y; Wu J; Wu X; Fu X; Schiff R; Davis CM; Robertson M; Ehli EA; Coarfa C; Mitsiades N; Song Y
J Med Chem; 2020 May; 63(9):4716-4731. PubMed ID: 32314924
[TBL] [Abstract][Full Text] [Related]
4. Structure-activity relationship and antitumor activity of 1,4-pyrazine-containing inhibitors of histone acetyltransferases P300/CBP.
Nie S; Wu F; Wu J; Li X; Zhou C; Yao Y; Song Y
Eur J Med Chem; 2022 Jul; 237():114407. PubMed ID: 35512565
[TBL] [Abstract][Full Text] [Related]
5. Valproic acid exposure decreases Cbp/p300 protein expression and histone acetyltransferase activity in P19 cells.
Lamparter CL; Winn LM
Toxicol Appl Pharmacol; 2016 Sep; 306():69-78. PubMed ID: 27381264
[TBL] [Abstract][Full Text] [Related]
6. Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor.
Bowers EM; Yan G; Mukherjee C; Orry A; Wang L; Holbert MA; Crump NT; Hazzalin CA; Liszczak G; Yuan H; Larocca C; Saldanha SA; Abagyan R; Sun Y; Meyers DJ; Marmorstein R; Mahadevan LC; Alani RM; Cole PA
Chem Biol; 2010 May; 17(5):471-82. PubMed ID: 20534345
[TBL] [Abstract][Full Text] [Related]
7. E2A proteins enhance the histone acetyltransferase activity of the transcriptional co-activators CBP and p300.
Hyndman BD; Thompson P; Bayly R; Côté GP; LeBrun DP
Biochim Biophys Acta; 2012 May; 1819(5):446-53. PubMed ID: 22387215
[TBL] [Abstract][Full Text] [Related]
8. Acetyltransferases CBP/p300 Control Transcriptional Switch of β-Catenin and Stat1 Promoting Osteoblast Differentiation.
Zhang L; Zhu K; Xu J; Chen X; Sheng C; Zhang D; Yang Y; Sun L; Zhao H; Wang X; Tao B; Zhou L; Liu J
J Bone Miner Res; 2023 Dec; 38(12):1885-1899. PubMed ID: 37850815
[TBL] [Abstract][Full Text] [Related]
9. Discovery of DS-9300: A Highly Potent, Selective, and Once-Daily Oral EP300/CBP Histone Acetyltransferase Inhibitor.
Kanada R; Kagoshima Y; Suzuki T; Nakamura A; Funami H; Watanabe J; Asano M; Takahashi M; Ubukata O; Suzuki K; Aikawa T; Sato K; Goto M; Setsu G; Ito K; Kihara K; Kuroha M; Kohno T; Ogiwara H; Isoyama T; Tominaga Y; Higuchi S; Naito H
J Med Chem; 2023 Jan; 66(1):695-715. PubMed ID: 36572866
[TBL] [Abstract][Full Text] [Related]
10. RNA Binding to CBP Stimulates Histone Acetylation and Transcription.
Bose DA; Donahue G; Reinberg D; Shiekhattar R; Bonasio R; Berger SL
Cell; 2017 Jan; 168(1-2):135-149.e22. PubMed ID: 28086087
[TBL] [Abstract][Full Text] [Related]
11. Activation of p300 histone acetyltransferase activity and acetylation of the androgen receptor by bombesin in prostate cancer cells.
Gong J; Zhu J; Goodman OB; Pestell RG; Schlegel PN; Nanus DM; Shen R
Oncogene; 2006 Mar; 25(14):2011-21. PubMed ID: 16434977
[TBL] [Abstract][Full Text] [Related]
12. Histone deacetylase inhibitors synergize p300 autoacetylation that regulates its transactivation activity and complex formation.
Stiehl DP; Fath DM; Liang D; Jiang Y; Sang N
Cancer Res; 2007 Mar; 67(5):2256-2264. PubMed ID: 17332356
[TBL] [Abstract][Full Text] [Related]
13. Characteristics of anticancer activity of CBP/p300 inhibitors - Features of their classes, intracellular targets and future perspectives of their application in cancer treatment.
Strachowska M; Robaszkiewicz A
Pharmacol Ther; 2024 May; 257():108636. PubMed ID: 38521246
[TBL] [Abstract][Full Text] [Related]
14. Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours.
Lasko LM; Jakob CG; Edalji RP; Qiu W; Montgomery D; Digiammarino EL; Hansen TM; Risi RM; Frey R; Manaves V; Shaw B; Algire M; Hessler P; Lam LT; Uziel T; Faivre E; Ferguson D; Buchanan FG; Martin RL; Torrent M; Chiang GG; Karukurichi K; Langston JW; Weinert BT; Choudhary C; de Vries P; Van Drie JH; McElligott D; Kesicki E; Marmorstein R; Sun C; Cole PA; Rosenberg SH; Michaelides MR; Lai A; Bromberg KD
Nature; 2017 Oct; 550(7674):128-132. PubMed ID: 28953875
[TBL] [Abstract][Full Text] [Related]
15. The structural basis of protein acetylation by the p300/CBP transcriptional coactivator.
Liu X; Wang L; Zhao K; Thompson PR; Hwang Y; Marmorstein R; Cole PA
Nature; 2008 Feb; 451(7180):846-50. PubMed ID: 18273021
[TBL] [Abstract][Full Text] [Related]
16. Small-molecule inhibitors of acetyltransferase p300 identified by high-throughput screening are potent anticancer agents.
Yang H; Pinello CE; Luo J; Li D; Wang Y; Zhao LY; Jahn SC; Saldanha SA; Chase P; Planck J; Geary KR; Ma H; Law BK; Roush WR; Hodder P; Liao D
Mol Cancer Ther; 2013 May; 12(5):610-20. PubMed ID: 23625935
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and biological evaluation of a novel spiro oxazolidinedione as potent p300/CBP HAT inhibitor for the treatment of ovarian cancer.
Ding H; Pei Y; Li Y; Xu W; Mei L; Hou Z; Guang Y; Cao L; Li P; Cao H; Bian J; Chen K; Luo C; Zhou B; Zhang T; Li Z; Yang Y
Bioorg Med Chem; 2021 Dec; 52():116512. PubMed ID: 34801827
[TBL] [Abstract][Full Text] [Related]
18. Is histone acetylation the most important physiological function for CBP and p300?
Bedford DC; Brindle PK
Aging (Albany NY); 2012 Apr; 4(4):247-55. PubMed ID: 22511639
[TBL] [Abstract][Full Text] [Related]
19. Histone acetyltransferase promotes fluoride toxicity in LS8 cells.
Deng H; Fujiwara N; Cui H; Whitford GM; Bartlett JD; Suzuki M
Chemosphere; 2020 May; 247():125825. PubMed ID: 31927229
[TBL] [Abstract][Full Text] [Related]
20. Selective inhibition of p300 HAT blocks cell cycle progression, induces cellular senescence, and inhibits the DNA damage response in melanoma cells.
Yan G; Eller MS; Elm C; Larocca CA; Ryu B; Panova IP; Dancy BM; Bowers EM; Meyers D; Lareau L; Cole PA; Taverna SD; Alani RM
J Invest Dermatol; 2013 Oct; 133(10):2444-2452. PubMed ID: 23698071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]